EGFR and non-small cell lung carcinoma: Treatment NSCLC harbouring mutant epidermal growth factor receptor (EGFR) with specific tyrosine kinase inhibitor (TKI) has led to remarkable tumor shrinkage and improvement in progression-free survival (PFS) and quality of life compared with standard chemotherapy [7–10].